Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations (TOPARP-B): A Multicentre, Open-Label, Randomised, Phase 2 TrialLancet Oncol 2019 Dec 02;[EPub Ahead of Print], J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, C Ralph, S Jain, M Varughese, O Parikh, S Crabb, A Robinson, D McLaren, A Birtle, J Tanguay, S Miranda, I Figueiredo, G Seed, C Bertan, P Flohr, B Ebbs, P Rescigno, G Fowler, A Ferreira, R Riisnaes, R Pereira, A Curcean, R Chandler, M Clarke, B Gurel, M Crespo, D Nava Rodrigues, S Sandhu, A Espinasse, P Chatfield, N Tunariu, W Yuan, E Hall, S Carreira, JS de Bono
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.